Larvol Delta - BXCL701201-A-Trial-of-BXCL701-and-Pembrolizumab-in-Patients-With-mCRPC-Either-Small-Cell-Neuroendocrine-Prostate-Cancer-or-Adenocarcinoma-Phenotype

talabostat (BXCL701) - BioXcel

Keytruda (pembrolizumab) - Merck (MSD)

http://clinicaltrials.gov/ct2/show/NCT03910660

May 16, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next